• Latest Posts

Sanofi drug reduces disease activity in relapsing MS

Neuraxpharm’s expansion into the Netherlands takes it from two to 20 countries in six years

First of a kind multiple sclerosis biosimilar natalizumab accepted by US Food and Drug Association

First-ever Marketing Authorization Application for biosimilar targeting MS filed

EMA Approvals for Multiple Sclerosis Highlight Treatment Shortfalls


Phase III Fail for MedDay’s Multiple Sclerosis Treatment

European Biotechs Showcase Multiple Sclerosis Treatments in Stockholm

Blocking Hidden Viral Protein Shows Promise for Treating Multiple Sclerosis

Italian Biotech Raises Big Series A for ‘Gene Therapy 2.0’

More News! 18 May 2018

New Treatment for Rare Neurologic Eye Disease on Horizon from Spanish Biotech

More News! 26 Mar 2018

Attacking an Ancient Virus Slows Multiple Sclerosis in Phase II